Tirzepatide for Severe Obesity in Adolescents Without Diabetes
AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 837-841
DOI: 10.1016/j.aed.2026.07.013 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Reham Yehia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital Los Angeles and Keck School of Medicine of USC, Department of Pediatrics, Center for Endocrinology, Diabetes and Metabolism, Los …. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background/Objective: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, has demonstrated substantial weight reduction in adults but remains unapproved for obesity treatment in adolescents without diabetes. The objective of this report is to describe adolescents with severe obesity without diabetes treated with tirzepatide, highlighting body mass index reduction (BMI), metabolic outcomes, and tolerability in a safety-net setting. Case Presentation: Five adolescents (ages 11-16 years; 3 males, 2 females) presented with severe obesity (BMI 37-52 kg/m2; ≥120% of the 95th percentile). Baseline percent of the 95th percentile BMI (%BMIp95) ranged from 125% to 200%. Tirzepatide was initiated at 2.5 mg weekly and titrated to 10 to 15 mg. Over 6 to 18 months, %BMIp95 decreased across all patients, with reductions from baseline to 18 months of 190% to 158%, 200% to 145%, 150% to 85%, and 135% to 85%; one patient decreased from 125% to 85% by 12 months. These changes corresponded to absolute weight reductions of 17.6 to 40 kg (13%-36%). Hemoglobin A1c decreased or remained within the normal range (4.3%-5.6%), triglycerides declined, and alanine aminotransferase normalized. No hypoglycemia or pancreatitis occurred. No treatment discontinuations were documented during available follow-up.
Discussion
Marked weight reduction and metabolic improvement observed in these youth with obesity, without type 2 diabetes are consistent with outcomes reported in adult populations receiving tirzepatide, with greater weight loss associated with improved cardiometabolic parameters.
Conclusion
This series highlights substantial weight reduction among adolescents with severe obesity treated with tirzepatide. Participants tolerated therapy during observed follow-up without reported gastrointestinal adverse effects, supporting further investigation in pediatric populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Children's Hospital Los Angeles and Keck School of Medicine of USC, Department of Pediatrics, Center for Endocrinology, Diabetes and Metabolism, Los Angeles, California.
Förderung
- NIDDK NIH HHS
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases
Zitieren
APA
Yehia, R., Patel, P., Sousa, E., & Vidmar, A. P. (2026). Tirzepatide for Severe Obesity in Adolescents Without Diabetes. AACE Endocrinology and Diabetes, 13(5), 837-841. https://doi.org/10.1016/j.aed.2026.07.013
Vancouver
Yehia R, Patel P, Sousa E, Vidmar AP. Tirzepatide for Severe Obesity in Adolescents Without Diabetes. AACE Endocrinology and Diabetes. 2026;13(5):837-841. doi:10.1016/j.aed.2026.07.013
BibTeX
@article{Yehia2026,
author = {Yehia, Reham and Patel, Priya and Sousa, Emily and Vidmar, Alaina P},
title = {Tirzepatide for Severe Obesity in Adolescents Without Diabetes},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {5},
pages = {837--841},
doi = {10.1016/j.aed.2026.07.013}
}
EUVIMED